PRESS RELEASE

LightSight

Applied Biosystems has launched a drug discovery application that enables pharmaceutical companies and contract research organisations to more quickly and accurately screen drug candidates – LightSight Software for Metabolite Identification.

Identifying drug metabolites, which are the intermediates and products of metabolism, is key to the drug discovery process, because the metabolites formed could be potentially toxic or could be more efficacious than the drug itself. Applied Biosystems/MDS SCIEX’s metabolite ID software, enables drug discovery scientists to examine thousands of drug candidates and quickly decide which fail to meet their requirements

More than 100 pharmaceutical scientists from 35 companies worldwide provided input and feedback for the development of the LightSight Software, resulting in a comprehensive metabolite ID package attuned to the way metabolite ID labs operate.

Because the application is designed to be workflow-based for the metabolite ID lab, it allows users to streamline their work, simplifying the process and allowing for a larger number of experiments to be performed without an increase in resources or training.

Feature

For functionality and security for externalised research, software providers have turned to the cloud, writes Sophia Ktori

Feature

Robert Roe looks at the latest simulation techniques used in the design of industrial and commercial vehicles

Feature

Robert Roe investigates the growth in cloud technology which is being driven by scientific, engineering and HPC workflows through application specific hardware

Feature

Robert Roe learns that the NASA advanced supercomputing division (NAS) is optimising energy efficiency and water usage to maximise the facility’s potential to deliver computing services to its user community

Feature

Robert Roe investigates the use of technologies in HPC that could help shape the design of future supercomputers